Senhwa Biosciences, Inc. previously has obtained IND application approvals from the US FDA and Taiwan FDA with respect to the clinical trials of Silmitasertib (CX-4945) for treating community-acquired pneumonia (CAP) patients associated with viral infections (SARS-CoV-2 and Influenza). However, in consideration of strategy adjustment, the Company has decided to officially notify the National Cheng Kung University Hospital of early termination of the Phase II clinical trial of Silmitasertib (CX-4945) for the treatment of hospitalized patients with COVID-19. For the information about the Phase II clinical trial ofSilmitasertib (CX-4945) for the treatment of community-acquired pneumonia (CAP) patients caused by pan-viral infections, please refer to the company?s major announcement on December 25, 2023.

A single clinical trial result does not reflect the success or failure of new drug development and launch in the future. Investors should make prudent judgments and investments. Countermeasures:With the discontinuation of this Phase II clinical trial of Silmitasertib (CX-4945) for the treatment of hospitalized patients with COVID-19, the Company is able to allocate resources to other clinical plans with more cost effective structures.